Section 3 of 6
Product information and disease description
280 evidence topics · 111 sources
Product description
Phase of product development
Regulatory status: Submission planned; NDA submission planned by the end of 2026
Launch
No evidence found.
Approval timing assumed in the company's exclusivity projection: second half of 2027
Analyst assumption of U.S. market entry in 2027 (LifeSci Capital, June 2026)
Development phase: phase 3 in moderately to severely active ulcerative colitis
NDA submission timing: company guidance from January 2026 to May 2026
Marketing authorization application to the EMA: planned for the second half of 2026, July 2025 statement
EU paediatric investigation plan for ulcerative colitis: modification accepted in March 2025
| Field | Quoted record |
|---|---|
| Decision | “EMA/PE/0000189672” |
| Decision date | “of 20 March 2025” |
| Condition | “Treatment of ulcerative colitis” |
| Indication targeted by the PIP | “Treatment of patients diagnosed with moderately to severely active ulcerative colitis (UC)” |
| Paediatric subset concerned | “From 2 years to less than 18 years of age” |
| Waiver | “the paediatric population from birth to less than 2 years of age;” |
| Paediatric clinical study | “2-part, multi-centre, double-blind induction and maintenance study to evaluate the efficacy, safety, tolerability and PK of obefazimod in paediatric patients with moderately to severely active ulcerative colitis aged from 2 years to less than 18 years.” |
| Date of completion of the PIP | “By June 2029” |
| Deferral | “Yes” |
EU paediatric investigation plan: modification accepted in June 2024
Product information
Generic, brand name and therapeutic class of product
Generic name, chemical name, and identifiers
| Field | Quoted record |
|---|---|
| International nonproprietary name (Latin) | “obefazimodum” |
| International nonproprietary name (English) | “obefazimod” |
| Chemical name | “8-chloro-N-[4-(trifluoromethoxy)phenyl]quinolin-2-amine” |
| Functional description | “immunomodulator” |
| Molecular formula | “C16H10ClF3N2O” |
| CAS registry number | “1258453-75-6” |
| INN list | “Proposed INN: List 125” |
Development code: ABX464
Brand name
No evidence found.
Therapeutic class: oral small molecule miR-124 enhancer
“Obefazimod is an oral small molecule that selectively enhances the expression of a single micro-RNA (miRNA), miR-124.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obefazimod (ABX464) is a first-in-class, oral small molecule that enhances microRNA-124 (miR-124) biogenesis, suppressing STAT3 and CCL2 signaling, reducing Th17 polarization and macrophage activation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer: Abivax
Dosage forms and strengths
Investigational dosage form: 25 mg and 50 mg oral capsules
| Field | Quoted record |
|---|---|
| International nonproprietary name | “Obefazimod” |
| Strengths | “25 mg capsule”; “50 mg capsule” |
| Route of administration | “Oral” |
| Packaging | “Each blister card (=kit) contains 35 capsules.” |
| Blister cards | “IMP will be packaged in child-resistant blister cards with blinded labels.” |
Pharmaceutical forms in the EU paediatric investigation plan: hard capsule and an age-appropriate oral liquid
| Field | Quoted record |
|---|---|
| Pharmaceutical forms | “Capsule, hard”; “Age-appropriate oral liquid dosage form” |
| Route of administration | “Oral use” |
| Quality-related study | “Development of an age-appropriate oral liquid dosage form.” |
Pediatric 50 mg minitablet formulation compared with the adult capsule in healthy participants (ABX464-911)
Commercial dosage form and strengths
No evidence found.
Average sales price and wholesale acquisition cost
Wholesale acquisition cost and average sales price
Not applicable.
Analyst assumption of a net annual U.S. price at launch of US$78,000 (LifeSci Capital, June 2026)
American hospital formulary service (AHFS), or other drug classification
AHFS classification
No evidence found.
WHO INN functional description: immunomodulator
NCI Drug Dictionary: small molecule binder of the cap binding complex
Indication
Proposed indication: adults with moderately to severely active ulcerative colitis
Population of the pivotal ABTECT trials: inadequate response to conventional or advanced therapy
Indication targeted by the EU paediatric investigation plan
Crohn's disease in development: phase 2b ENHANCE-CD, induction topline results expected mid-2027
ENHANCE-CD induction results timing, January to May 2026, superseded in June 2026
Pharmacology
Mechanism of action
Binding to the cap binding complex and splicing of a long noncoding RNA that houses miR-124
“ABX464 is a small molecule that binds to the cap binding complex (CBC)2, a complex at the 5′-end of the pre-mRNA transcript that promotes the initial interaction with transcription and processing machinery3–5.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Here, using RNA CaptureSeq and deep sequencing, we report that ABX464 enhances the splicing of HIV RNA in infected PBMCs from six healthy individuals and also the expression and splicing of a single long noncoding RNA to generate the anti-inflammatory miR-124 both ex vivo and in HIV patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While ABX464 has no effect on pre-mRNA splicing of cellular genes, depletion of CBC complex by RNAi leads to accumulation of intron retention transcripts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These results imply that ABX464 did not inhibit the function of CBC in splicing but rather strengthens it under pathological condition like inflammation and HIV infection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacologically active N-glucuronide metabolite acting on the same target
Downstream effects on Th17 cells, macrophages, and cytokines
miR-124 as a modulator of inflammation: review by the discovery group
“MiR-124 is a crucial modulator of inflammation and innate immunity that could provide therapeutic restitution of physiological pathways lost in inflammatory diseases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A recently discovered small quinoline, ABX464, was shown to upregulate miR-124 in human immune cells.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacodynamics
miR-124 expression in rectal biopsies and blood: phase 2b induction trial
“The number of miR-124 copies was determined by ddPCR, at baseline and after 8 weeks of treatment, in rectal biopsies and blood samples from patients who received ABX464 (25, 50, or 100 mg) or placebo during a phase 2b trial (10) (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 8, the number of miR-124 copies was significantly higher in the treatment groups than in the placebo group (the mean number of copies/cell: placebo, 746; ABX464 [25, 50, and 100 mg], 8,345, 8,347, and 9,171, respectively; Figure 4b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 8, the number of miR-124 copies was significantly higher in each treatment group than in the placebo group (the mean number of copies/cell: placebo, 28.93; ABX464 [25, 50, and 100 mg], 4,598, 8,517, and 13,753, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 576 rectal biopsies from 139 patients and 1,104 blood samples from 229 patients who received ABX464 (25, 50, or 100 mg) or placebo were analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum cytokines: phase 2b induction trial
“For the cell and cytokine (IL1b, IL4, IL6, IL10, IL23, IFNγ, CCL2, TNF-α, and IL17a) analysis in serum samples from patients who received either ABX464 during the phase 2b trial (10), significant changes vs placebo were seen only for IL17a, at all doses, with no dose-dependent effect (Figure 5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, a reduction in Th17 population and IL17a expression was observed in serum samples, but it was not dose-dependent (see Discussion).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
miR-124 expression and serum IL-17A and IL-6: ABTECT induction trials
miR-124 expression through 96 weeks: phase 2b open-label maintenance study
“Treatment with obefazimod 50 mg significantly enhanced the expression of miR-124 in blood and rectal tissue at weeks 48 and 96 (P < .001 vs. baseline) (Figure 6).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Enhanced expression of miR-124 was observed in both rectal tissue and blood of patients receiving obefazimod 50 mg during the OLM study, including those previously receiving placebo during the induction study (Table S2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
miR-124 induction and Th17 cells in human immune cells: in vitro studies
“In this analysis, ABX464 treatment resulted in significant upregulation of miR-124 levels; specifically, the increases in miR-124 levels were 9-fold in PBMCs (Figure 1a), 7-fold in purified CD4+ cells (Figure 1b), and 9-fold in macrophages (Figure 1c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ABX464 treatment did not change Th1+ cells but significantly decreased Th17 cells (−39.1%, P = 0.0002) or Th17+ like Th1+ (Figure 2b), confirmed by significant decreases (−50.8%, P < 0.0001) in IL17a-secreting cells (Figure 2c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dextran sodium sulfate colitis in mice
“Treatment with ABX464 significantly reversed the increases in several proinflammatory cytokines induced by DSS (GM-CSF, IL10, IL34, TPO, LIF, CXCL12, IL6, and CCL2) and maintained their levels close to those of healthy H2O-treated mice (Figure 7a–c).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ABX464 treatment reversed the DSS-induced upregulation of IL17a-secreting cells (−54.2%, P < 0.0001 vs untreated DSS mice) and maintained them at a level equivalent to that in healthy H2O-treated mice (P > 0.9999) (Figure 8a), which further support the effect of ABX464 on adaptive immunity through the reduction of the Th17-positive and CD4-positive subsets.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ABX464 treatment strongly attenuated DSS-induced colitis in mice and produced a long-term protection against prolonged DSS-exposure after drug cessation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, RNA profiling analysis revealed the capacity of ABX464 to induce the expression of IL-22, a cytokine involved in colitis tissue repair, both in DSS-treated mice and in LPS-stimulated bone marrow-derived macrophages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Importantly, anti-IL-22 antibodies significantly reduced the protective effect of ABX464 on colitis in DSS-treated mice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cytokine and chemokine levels under dysregulated inflammatory conditions: preclinical studies
Anti-fibrotic activity in human intestinal fibroblasts and chronic TNBS colitis in mice
Nonclinical toxicology and genotoxicity
Pharmacokinetics
Absorption and conversion to the N-glucuronide metabolite: first-in-human single ascending dose study
“A single oral dose of ABX464 (50, 100, 150 or 200 mg) was administered on the morning of day 0 after overnight fasting, with follow-up for 45 days.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ABX464's C max was observed approximately 2 h after administration in all groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“ABX464 was rapidly and substantially metabolized into ABX464-NGlc.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The C max of ABX464-NGlc was observed approximately 4 h post-dose and was about 160-fold higher than that of the parent with a much longer t 1/2 (90-110 h).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The ratio of metabolite to parent drug was consistent across the complete dose range.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Half-lives of the parent compound and the metabolite after repeated doses
Metabolism by glucuronidation and time to steady state
Effect of food on exposure
“The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The apparent terminal elimination half-lives (t1/2s) under fed and fasted conditions were comparable, at about 0.80 h.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median time to maximum concentration (Tmax) was delayed from 1.5 to 2.8 h, and the ratio of the AUC0–∞ obtained under fed conditions to the AUC0–∞ obtained under fasted conditions (Frel) was 2.69.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The increases in Cmax and AUC0–∞ of the metabolite ABX464–N-glucuronide (ABX464-NGlc) were, however, much more limited when ABX464 was given with food.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The t1/2s were also comparable under the two conditions (around 100 h).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Interindividual variability under fed and fasted conditions
“Interindividual variability tended to decrease when ABX464 was given with food, since the CVs of AUC0–t and AUC0–∞ under fasted conditions were 67% and 57% compared to 42% and 37%, respectively, under fed conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Hepatic impairment: phase 1 pharmacokinetic study in mild and moderate impairment
Renal and hepatic laboratory exclusions in the ABTECT induction trials
Pregnancy, breastfeeding, and contraception in the ABTECT trials
Pregnancy: reports in ABTECT maintenance Part 1
| Event | Placebo (N = 192) | Obefazimod 25 mg (N = 193) | Obefazimod 50 mg (N = 195) |
|---|---|---|---|
| Pregnancy | “0” | “0” | “2 (1.1%)” |
Contraception for male participants: phase 1 study in healthy Japanese men
Older adults: participants aged 65 years or older in the ABTECT induction trials
Pediatric development: European paediatric investigation plan
Adolescents aged 16 to 17 years in the ABTECT induction trials
Pediatric minitablet formulation: relative bioavailability study in adults
Drug/Drug, drug/disease interactions
Effects of other drugs on Obefazimod
Fluvoxamine, a CYP1A2 inhibitor: obefazimod exposure in healthy participants (Part B)
| Parameter | Day 1, obefazimod 50 mg alone | Day 11, obefazimod 50 mg with fluvoxamine 100 mg |
|---|---|---|
| Participants analyzed | “25” | “25” |
| Cmax, ng/mL, mean (SD) | “23.2(12.5)” | “33.4(19.0)” |
| AUC, h*ng/mL, mean (SD) | “55.2(25.7)” | “73.0(34.2)” |
Fluvoxamine: exclusions from the pharmacokinetic analysis
Fluvoxamine: sponsor plain-language summary of results
Effects of Obefazimod on other drugs
Caffeine, a CYP1A2 substrate: caffeine exposure with single and repeated obefazimod doses (Part A)
| Parameter | Day 1, caffeine 50 mg alone | Day 4, caffeine with obefazimod 50 mg | Day 17, caffeine with obefazimod after 14 days of daily dosing |
|---|---|---|---|
| Participants analyzed | “22” | “22” | “22” |
| Caffeine Cmax, ng/mL, mean (SD) | “931(285)” | “930(278)” | “564(242)” |
| Caffeine AUC, h*ng/mL, mean (SD) | “7420(4760)” | “5460(2740)” | “1560(719)” |
Caffeine: design of the inhibition and induction assessments
Caffeine: sponsor plain-language summary of results
Rosuvastatin: phase 1 interaction study in healthy men
Combined oral contraceptive (ethinyl estradiol and drospirenone): phase 1 interaction study in healthy women
Completed interaction studies supporting the planned NDA
Dosing and administration
Dosage
Phase 3 doses: 25 mg and 50 mg once daily for induction and maintenance
Fixed dose in ABTECT induction: one capsule daily, no dose adjustment
Maintenance dose strategy: company report of regulatory consultant support for both 25 mg and 50 mg
Dose escalation from 25 mg to 50 mg after relapse in ABTECT maintenance Part 2
Dose de-escalation from 50 mg to 25 mg in the long-term open-label Study 108
Phase 2b dose range: 25 mg, 50 mg, and 100 mg once daily
Administration
Oral, once daily in the morning with food
Effect of food on exposure: healthy volunteers, 50 mg
“The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It was concluded that food has a significant impact on the levels of ABX464 in plasma with a delay in absorption and increased relative bioavailability, with a lesser impact on its biotransformation into ABX464-NGlc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Access and distribution
Commercial organization: market access, pricing, and patient services leadership appointed in July 2026
Commercial preparation for a U.S. launch
Distribution and channel strategy under board review
Commercial supply: outsourced manufacturing and a second source manufacturer
Specialty pharmacy network and patient support program
No evidence found.
Co-prescribed/Concomitant therapies
Background oral 5-ASA and oral corticosteroids permitted at a stable dose in ABTECT induction
Concomitant therapies prohibited in ABTECT induction: immunosuppressants and advanced therapies
Concomitant oral corticosteroids in ABTECT maintenance: randomization stratification and baseline use
Corticosteroid-free clinical remission as a maintenance key secondary endpoint
Combination therapy with obefazimod: preclinical evaluation
Effect of Obefazimod on quality measures
MIPS Quality ID 275: hepatitis B virus status assessed before anti-TNF therapy in IBD
Product-specific effect on quality measures
No evidence found.
Product comparison
Network meta-analysis of phase 3 induction trials including obefazimod
“Thirty-three induction trials involving 17 therapies were included.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Upadacitinib demonstrated the highest relative efficacy for clinical remission (risk ratio, 6.90; 95% confidence interval, 3.54-12.45; P score, 0.95; high confidence) and endoscopic improvement (risk ratio, 5.29; 95% confidence interval, 3.38-8.28; P score, 0.97; moderate confidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Novel therapies, like obefazimod and subcutaneous guselkumab, may represent highly effective alternatives.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mechanism of action relative to authorized immunological treatments
Marketed and investigational classes named by the manufacturer as competitors
Company cross-trial comparison of maintenance clinical remission with approved UC products
Emerging oral small molecules for ulcerative colitis
Analyst comment on a possible boxed warning relative to JAK inhibitors and TL1A inhibitors
Place of product in therapy
Disease description
Definition and etiology
Disease definition: chronic inflammation of the rectum and colon
“Ulcerative colitis is a lifelong inflammatory disease affecting the rectum and colon to a variable extent.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ulcerative colitis (UC) is a chronic inflammatory condition of the colon, with a prevalence exceeding 400 per 100 000 in North America.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Etiology: genetic predisposition, environmental exposures, barrier defects, microbiota, and immune dysregulation
“Ulcerative colitis is thought to occur in people with a genetic predisposition following environmental exposures; gut epithelial barrier defects, the microbiota, and a dysregulated immune response are strongly implicated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affecting the colon and rectum. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been suggested to contribute to UC pathogenesis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Genetic susceptibility: shared loci with Crohn's disease, HLA associations, and low twin concordance
“Most genetic factors (67% of susceptibility loci) are shared between UC and Crohn’s disease (CD)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen human leukocyte antigen (HLA) allelic associations (mostly class II) are described for UC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thirdly, despite the identification of many susceptibility loci, genetics explain only 19% of disease heritability in UC 18. The concordance rate amongst monozygotic twins for UC is only 6.3% (compared to nearly 60% in CD).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Environmental factors: Westernization, smoking cessation, and appendicitis
“Westernisation is accompanied by new urban lifestyle, exposure to pollution, change in diet, access to antibiotics, better hygiene, and fewer infections, all considered as general contributory factors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Appendicitis and smoking are protective in UC; smoking cessation can precede UC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although the reasons for this increase remain incompletely understood, evidence suggests environmental factors associated with Westernization of society” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“may have substantially contributed by altering mucosal immune responses to the intestinal microbiome in genetically susceptible individuals” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epidemiology
Incidence of Ulcerative colitis
United States: 6.3 per 100,000 person-years in pooled commercial, Medicare, and Medicaid claims
“Overall, the incidence of ulcerative colitis (6.3, 95% CI 6.1–6.6) was higher than that of Crohn’s disease (4.1, 95% CI 3.9–4.3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of IBD, ulcerative colitis and Crohn’s disease peaked in the third decade of life, decreased to a stable relatively stable level across the 4th to 8th decades, and declined further beyond age 80.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, among children, the incidence of Crohn’s disease was higher than ulcerative colitis (Figure 1, Supplemental Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: age at onset
Global: highest incidence in Scandinavia, with a ceiling of about 40 per 100,000
“The highest incidence of IBD, particularly UC, has been reported in Scandinavia (Fig. 1a,b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In Denmark, incidence steadily increased from the 1970s (CR-I: 2.05–3.55 for CD; 6.50–9.12 for UC) to 1990s (CR-I: 7.30–10.68 for CD; 13.18–20.99 for UC) and to 2010s (CR-I: 12.62–15.84 for CD; 22.21–30.64 for UC)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The highest ever reported UC incidence was 73.7 in the Faroe Islands in 2011” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Thus, 40 per 100,000 serves as a ceiling threshold for the incidence of CD or UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global: rising incidence in newly industrialized regions of Asia
“By 2000, the incidence had increased tenfold reaching 4.77 and 1.27 for UC and CD, respectively (Supplementary Fig. 9a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“South Korea showed similar patterns, with low incidence in the 1980s (CR-I: 0–0.03 for CD; 0.21–0.33 for UC) increasing steadily into the 2010s (CR-I: 2.20–3.20 for CD; 4.11–6.27 for UC)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Regions with slower economic development experienced a delayed onset of rapidly rising incidence, as seen in China and Malaysia, where incidence substantially increased after 2000 (Supplementary Figs. 11a and 12a).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global: ratio of ulcerative colitis to Crohn's disease by epidemiologic stage
“We observed a significant difference (P < 0.001) in the UC:CD ratio across the three epidemiologic stages: a median ratio of 3.24:1 in stage 1, decreasing to 1.87:1 in stage 2 and further to 1.54:1 in stage 3 (Supplementary Fig. 17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On the basis of the assumption that Canada, the United States, most of western Europe, Australia and New Zealand are currently in stage 3, we assigned stage classifications to approximately 65% of our dataset (Supplementary Fig. 16).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of Ulcerative colitis
United States: 378 per 100,000 and an estimated 1.253 million people with ulcerative colitis
“The age-, sex- and insurance-standardized prevalence per 100,000 population was 721 (95% CI 717 – 726) for IBD, 378 per 100,000 (95% CI 375 – 382) for ulcerative colitis and 305 (95% CI 302 – 308) for Crohn’s disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Extrapolated to the 2020 census estimate of 331,449,281 US population, there is an estimated 2.390 million Americans with IBD, 1.253 million with ulcerative colitis and 1.011 million with Crohn’s disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, the ratio of ulcerative colitis to Crohn’s disease was higher in Asian (1.6:1) and Hispanic (1.8:1) than in White (1.2:1) or Black (1.2:1) Americans.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: prevalence per 100,000 under alternative case definitions and enrollment periods
| Prevalence definition | Minimum enrollment | Prevalence per 100,000 (95% CI) |
|---|---|---|
| Primary | 4 years | “378 (375–382)”View highlighted excerpt for this quote |
| Secondary | 4 years | “438 (435–441)”View highlighted excerpt for this quote |
| Primary | 1 year | “312 (310–314)”View highlighted excerpt for this quote |
| Secondary | 1 year | “358 (356–361)”View highlighted excerpt for this quote |
United States: prevalence exceeding 400 per 100,000 in North America
United States: Medicare fee-for-service beneficiaries
United States: moderately to severely active disease, about 22% of patients in a given year (ICER 2020, citing the Crohn's & Colitis Foundation)
Moderately to severely active disease at diagnosis: population-based inception cohorts
“In a cohort of patients diagnosed in Copenhagen county between 1962–93, disease course was characterized as indolent, moderate or aggressive in 13%, 73% and 14% of patients, respectively, within the first 5-years of diagnosis; in the same region, in a cohort of patients diagnosed between 2003–04, early disease activity was characterized as mild in 76%, and moderate-to-severe in 24% (23,24).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
United States: company estimates of moderate-to-severe patients and advanced therapy use
United States: advanced therapy use after diagnosis in commercially insured adults, 2007 to 2023
“Among 3,893 patients with newly diagnosed UC (age at diagnosis, 41±14y; 52% male; 80% White, 7.2% Black and 8.2% Hispanic patients) followed over 4.2±3.0y, 5-year risk of IBD-related hospitalization, colectomy and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs. White patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative 1- and 5y use of advanced therapy was 17% (95% CI, 15–18) and 29% (95% CI, 27–31), respectively (Table 1). In a more contemporary cohort of patients diagnosed in 2019–23, the corresponding rate was 27% (95% CI, 24–29) and 38% (95% CI, 34–41), respectively (aHR, 3.43 [95% CI, 2.86–4.13]) (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative 1- and 5y use of TNF antagonists and non-TNF-targeting advanced therapy in the more contemporary cohort was 19% (95% CI, 16–21) and 26% (95% CI, 23–29), and 12% (95% CI, 10–14) and 27% (95% CI, 24–31), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global: prevalence ranges by epidemiologic stage and projected growth
“The clear distinctions across stages define the CRs for the incidence and prevalence of IBD” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“stage 1: CR-I = 0.1–1.2, CR-P = 1.2–10.5; stage 2: CR-I = 3.3–10.6, CR-P = 31.2–100.5; stage 3: CR-I = 18.1–34.1, CR-P = 362.9–660.1 (Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prevalence remains consistently low in regions classified as stage 1. Prevalence noticeably increases in stage 2 and then rises rapidly in stage 3 (Extended Data Fig. 2).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A slowing of prevalence growth rates was also observed in central difference approximations for both CD and UC (Supplementary Fig. 18c,d).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Natural history, survival, and mortality
Disease course: relapsing and remitting, with relapse in 70% to 80% by 10 years
“Majority of patients have a mild-moderate course, most active at diagnosis and then in varying periods of remission or mild activity; about 10–15% patients experience an aggressive course, and the cumulative risk of relapse is 70–80% at 10 years. Almost 50% patients require UC-related hospitalization, and 5-year risk of re-hospitalization is ~50%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the 10y follow-up study of the IBSEN cohort, four different profiles of disease activity were reported by patients: remission or mild severity after initial period of high activity (55%), chronic intermittent symptoms (37%), chronic continuous symptoms (6%) and increase activity after period of low activity (1%) (18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease extent at diagnosis and proximal extension
“At diagnosis, the majority of patients had left-sided colitis (median 40.1%; IQR, 32.6–44.6); 30.5% (29.8–32.6) and 29.4% (25.3–34.7) were diagnosed with extensive colitis and proctitis, respectively (9–17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall rates of progression ranged from 12–30%, with cumulative 5-year risk of progression being approximately 13% (10,13,14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization and colectomy: contemporary US inception cohort
“Cumulative 5y risk of all-cause and IBD-related hospitalization was 17% (95% CI, 16–19) and 11% (95% CI, 10–12), respectively (Table 2). Risk of all-cause and IBD-related hospitalization remained stable over era of IBD diagnosis (Figure 2D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative 1- and 5y risk of colectomy was 2.2% (95% CI, 1.8–2.7) and 5.7% (95% CI, 4.8–6.7), respectively (Table 2). Cumulative 5y risk of colectomy was lower in the more contemporary cohort (patients diagnosed in 2019–23 vs. 2007–12: 4.2% vs. 6.7%; aHR, 0.58 [95% CI, 0.38–0.89]) (Figure 2E).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Colectomy: meta-analysis of population-based cohorts
“In patients with UC (26 studies), overall 1-, 5-, and 10-year risk of colectomy was 4.0% (95% CI,3.3–5.0), 8.8% (7.7–10.0) and 13.3% (11.3–15.5), respectively, with decline in risk over time (p<0.001). Corresponding contemporary risks were 2.8% (2.0–3.9), 7.0% (5.7–8.6) and 9.6% (6.3–14.2), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Life expectancy: about 5 years shorter than people without ulcerative colitis
Mortality: all-cause and cause-specific standardized mortality ratios
“The all-cause mortality summary SMR for inception cohort and population cohort UC studies was 1.19 (95% confidence interval, 1.06–1.35).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mortality from colorectal cancer, pulmonary disease, and nonalcoholic liver disease was increased, whereas mortality from cardiovascular disease was decreased.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“UC has not been associated with an increased mortality, as compared to the general population, except in one cohort (23, 57–62).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A meta-analysis of both administrative and inception population-based studies recently observed a pooled mortality rate of respectively 0.7% and 5.3% for elective and emergent surgery, respectively without significant decrease over time (39).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Overview: barrier disruption, dysbiosis, and abnormal mucosal immune activation
“A widely accepted framework suggests a complex contribution of environmental and host factors that increase the susceptibility of developing UC, and disease onset is triggered by events that perturb the mucosal barrier, alter the healthy balance of the gut microbiota, and abnormally stimulate gut immune responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ulcerative colitis is thought to occur in people with a genetic predisposition following environmental exposures; gut epithelial barrier defects, the microbiota, and a dysregulated immune response are strongly implicated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mucosal inflammation: continuous from the rectum and limited to the mucosa
“These clinical features include the almost-universal involvement of the rectum (the lowest part of the colon) as the first site where inflammation starts and the distinctively confluent nature of inflammation that ends with an abrupt demarcation and transition into normal colonic mucosa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epithelial barrier: impaired barrier and UC-specific epithelial susceptibility genes
“An impaired epithelial barrier is a pathogenic factor for UC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“UC-specific genes implicate epithelial dysfunction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With the histologic observation of subepithelial inflammation, many studies implicate an impaired epithelial barrier as a pathogenic factor for UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Microbiota: reduced diversity and loss of short-chain fatty acid producers
“The UC gut microbiome, virome, and mycobiome is less diverse over time” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A depletion of protective bacteria such as short-chain fatty acid (SCFA)-producing Ruminococcaceae and Lachnospiraceae that coincides with an expansion of pro-inflammatory microbes such as Enterobacteriaceae, including Escherichia coli, and Fusobacteriaceae has been noted 37, 38.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is not known if dysbiosis is a consequence of, or plays a causal role in, gut inflammation in UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immune response: innate activation, atypical Th2 response, and IL-23 and Th17 pathways
“Innate immune responses (neutrophils/macrophages) may promote a pathogenic adaptive (likely T-cell driven) response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Traditionally, UC is associated with a Th2 response with high IL-4, IL-5, and IL-13, whereas CD has a more dominant Th1/Th17 response 84.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These include the identification of IL-23 as a key driver of Th17 responses 86, genetic associations with IL-23 and its related genes 11, 87, and the presence of Th17 88 (and Th9 89) cells in UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blocking IL-23, however, is effective in UC, e.g. mirikizumab (anti-p19 subunit of IL-23) 92 and ustekinumab (anti-p40 subunit of IL-23) 93.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Diagnosis
Diagnostic approach: clinical, biological, endoscopic, and histological findings
ACG 2025 key concept statements: suspicion, exclusion of infection, and colonoscopy with biopsy
ACG 2025 recommendations: Clostridioides difficile testing and serologic antibody testing
Endoscopy and histology: extent by the Montreal classification
Biomarkers: fecal calprotectin, C-reactive protein, and serology
“People with UC require monitoring of symptoms and biomarkers of inflammation (eg, fecal calprotectin), and require colonoscopy at 8 years from diagnosis for surveillance of dysplasia. Risk stratification by disease location (eg, Montreal Classification) and disease activity (eg, Mayo Score) can guide management of UC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Disease activity assessment: Mayo score and the trial definition of moderately to severely active disease
Diagnostic delay: mean 2.0 years from symptom onset
Clinical presentation - signs and symptoms
Intestinal symptoms: bloody diarrhea, rectal bleeding, urgency, and tenesmus
“Patients usually present with bloody diarrhoea, and the diagnosis is based on a combination of clinical, biological, endoscopic, and histological findings.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“UC impairs quality of life secondary to inflammation of the colon causing chronic diarrhea and rectal bleeding.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Systemic symptoms: abdominal pain, weight loss, and fatigue
“In the Manitoba cohort, patients with UC reported high rates of fatigue and sleep difficulties, particularly those with active symptoms (67% and 72%, respectively), as compared to those with inactive UC (30% and 57%, respectively), and these rates were not significantly different than in patients with CD (51).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Severe disease: fulminant colitis, toxic megacolon, and Truelove and Witts criteria
Flares and bowel frequency: patient survey in 10 countries
“A high proportion (87%) of patients reported having experienced a flare in the past year, with an average of 4.3 flares (SD, 7.4) experienced.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported visiting the bathroom (for any reason, including to pass stool, air, blood, or mucus) a mean of 3.5 times (SD, 2.9) on their best day and 9.8 times (SD, 7.4) on their worst day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients typically experienced initial symptoms at a mean age of 30.0 years (standard deviation [SD], 12.7; median, 29) and were diagnosed with UC at a mean age of 32.0 years (SD, 12.2; median, 30; Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Extraintestinal manifestations: joint, skin, ocular, oral, and hepatobiliary
Psychological symptoms: anxiety and depression with active disease
Long-term morbidity
Colectomy: 10% to 20% of patients require proctocolectomy for refractory disease
“Although the therapeutic options are expanding, 10-20% of patients still require proctocolectomy for medically refractory disease.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5- and 10-year cumulative risk of colectomy is 10–15%; achieving mucosal healing is associated with lower risk of colectomy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Disease extent consistently influences risk of colectomy (OR 2.2; 95% CI, 1.1–4.3), with significantly higher risk in patients with extensive colitis (10y cumulative risk, 19%), followed by left-sided colitis (8%) and ulcerative proctitis (5%) (16,18,20).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Colorectal cancer: risk by disease duration and extent
“The risk of colorectal cancer after 20 years of disease duration is 4.5%, and people with UC have a 1.7-fold higher risk for colorectal cancer compared with the general population.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative probability of CRC at 10, 20, and 30 years after UC diagnosis was 0.4–0.6%, 1.1–5.4%, and 2.1–7.5%, respectively (43,44). This risk is increased in patients with pancolitis (SIR, 2.4–14.8) and left-sided colitis (SIR, 1.4–2.8), but not in patients with proctitis (41,45–47). Young age at diagnosis, male sex, extensive colitis, disease duration and concomitant primary sclerosing cholangitis have been consistently identified as risk factors of CRC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Colorectal cancer: Danish and Swedish cohort of 96,447 patients, 1969 to 2017
“During follow-up, we observed 1336 incident CRCs in the UC cohort (1·29 per 1000 person-years) and 9544 incident CRCs in reference individuals (0·82 per 1000 person-years; HR 1·66, 95% CI 1·57-1·76). In the UC cohort, 639 patients died from CRC (0·55 per 1000 person-years), compared with 4451 reference individuals (0·38 per 1000 person-years; HR 1·59, 95% CI 1·46-1·72) during the same time period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The excess risks declined over calendar periods: during the last 5 years of follow-up (2013-17, Sweden only), the HR for incident CRC in people with UC was 1·38 (95% CI 1·20-1·60, or one additional case per 1058 patients with UC per 5 years) and the HR for death from CRC was 1·25 (95% CI 1·03-1·51, or one additional case per 3041 patients with UC per 5 years).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Extraintestinal manifestations: joint, ocular, or skin manifestations in 27% of patients
“Fifty-two studies were included that reported on 352 454 patients. The prevalence of at least 1 joint, ocular, or skin extraintestinal manifestation in all IBD, UC, and CD was 24%, 27%, and 35% respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall risk of EIMs in patients with UC ranges from 7–17%, probably lower as compared to patients with CD, and approximately 1% patients may present with EIMs before UC diagnosis (13,16,64). Articular manifestations are the most frequently observed EIMs (8%), including peripheral arthritis (5.5%), and ankylosing spondylitis (1%), followed by cutaneous EIMs (1.3%), PSC (0.6%) and ocular manifestations (0.6%) (64,65).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The cumulative incidence of spondyloarthropathy was 5%, 14%, and 22% at 10, 20 and 30y after UC diagnosis (66)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serious infections, venous thromboembolism, and cardiovascular events: contemporary US inception cohort
“Cumulative 1- and 5y risk of serious infections in patients with UC was 5.3% (95% CI, 4.6–6.0) and 10.2% (95% CI, 9.1–11.4), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative 1- and 5y risks of VTE were 0.1% (95% CI, 0.0–0.1) and 0.3% (95% CI, 0.1–0.5), and of MACE, was 0.2% (95% CI, 0.1–0.3) and 0.9% (95% CI, 0.5–1.3), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disability: work disability 1.8 times that of the general population
“Patients with UC had 1.8 times higher risk of work disability (95% CI, 1.4–2.3) as compared to general population, and was comparable to that seen in patients with CD (56).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“While UC is not associated with an increased risk of mortality, it is associated with high morbidity and work disability.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of Ulcerative colitis
Humanistic burden and health-related quality of life
EQ-5D utilities, SIBDQ scores, and disease activity in 289 US and 1037 European adults with moderate-to-severe ulcerative colitis
“N = 289 and N = 1037 patient charts with linked surveys were included from the US and EU5, respectively. The disease activity distribution was as follows: active disease = 40.1% (US) and 33.6% (EU5); remission = 48.0 and 53.0%; deep remission = 11.9 and 13.3%. Patients with active disease reported significantly lower levels of EQ-5D health state utilities (adjusted mean [AdjM] = 0.87 [US] and 0.78 [EU5]) compared with remission (AdjM = 0.92 and 0.91) and deep remission (AdjM = 0.93 and 0.91) (all P < 0.05 compared with active disease within each region).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, patients with active disease also reported lower EQ-5D VAS and SIBDQ scores (adjusted means = 70.8 and 4.6, respectively) compared with patients in remission (adjusted means = 82.4 and 5.5) and deep remission (adjusted means = 88.6 and 5.9) (all P < 0.05).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with moderate-to-severe UC in the US and EU5, active disease was associated with significant impairments in HRQoL, work and leisure activities.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Disease control, flares, and emotional impact in the UC Narrative global survey of 2100 patients
“Surveys of patients with UC (self-reported diagnosis; n = 2100) and physicians (n = 1254) were completed across 10 countries by The Harris Poll between August 2017 and February 2018.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The majority of patients (82%) had moderate to severe UC (based on medication history; those who had only ever taken 5-aminosalicylates were excluded); 67% described their UC as controlled with few to no symptoms. On average, patients experienced 4.3 flares (standard deviation, 7.4) in the past year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Globally, the majority of patients with moderate to severe disease (84%) reported UC to be mentally exhausting; even patients with milder UC (75%) or patients who self-reported being in remission (82%) agreed. Most patients (65%) felt that UC controlled their life rather than them controlling their UC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients reported visiting the bathroom (for any reason, including to pass stool, air, blood, or mucus) a mean of 3.5 times (SD, 2.9) on their best day and 9.8 times (SD, 7.4) on their worst day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 21% and 15% of patients self-reported receiving a diagnosis of anxiety or depression, respectively, although this finding varied by country.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Bowel urgency and fecal urge incontinence in 200 US and 556 European patients with moderate-to-severe ulcerative colitis (CONFIDE)
“Surveys were completed by 200 US and 556 European patients and 200 US and 503 European HCPs. The most common UC symptoms experienced in the preceding month were diarrhea, bowel urgency, and increased stool frequency. Many patients (45.0% of US patients, 37.0% of European patients) reported wearing diapers/pads/protection at least once a week in the past 3 months due to fear/anticipation of fecal urge incontinence. The top reasons for declining participation in social events, work/school, and sports/exercise were due to bowel urgency and fear of fecal urge incontinence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Over 30% of US patients and 40% of European patients do not feel comfortable discussing bowel urgency with their HCP (Figure 3C). The most common reason was due to feeling embarrassed to do so” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Anxiety and depression symptoms in 30 118 adults with inflammatory bowel disease: meta-analysis of 77 studies
“Of 5544 studies identified, 77 fulfilled the eligibility criteria, including 30 118 patients in total. Overall, pooled prevalence of anxiety symptoms was 32·1% (95% CI 28·3-36·0) in 58 studies (I2=96·9%) and pooled prevalence of depression symptoms was 25·2% (22·0-28·5) in 75 studies (I2=97·6%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In studies that reported prevalence of anxiety or depression in patients with Crohn's disease and ulcerative colitis within the same study population, patients with Crohn's disease had higher odds of anxiety symptoms (OR 1·2, 95% CI 1·1-1·4) and depression symptoms (1·2, 1·1-1·4) than patients with ulcerative colitis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of symptoms of anxiety (57·6% [95% CI 38·6-75·4]) or depression (38·9% [26·2-52·3]) was higher in patients with active IBD than in patients with inactive disease (38·1% [30·9-45·7] for anxiety symptoms and 24·2% [14·7-35·3] for depression symptoms; ORs 2·5 [95% CI 1·5-4·1] for anxiety and 3·1 [1·9-4·9] for depression).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life with approved advanced therapies: network meta-analysis of 28 randomized controlled trials
“Twenty-eight RCTs were included; 26 reported HRQoL outcomes during induction and 15 during maintenance. During induction, clinically meaningful improvements in IBDQ were observed with upadacitinib, filgotinib, and guselkumab. During maintenance, upadacitinib 30 mg and vedolizumab showed HRQoL benefits, although clinical meaningfulness was not consistently demonstrated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“SF-36 improvements were modest overall, with upadacitinib and vedolizumab showing selective advantages, while WPAI-UC benefits were observed with upadacitinib, vedolizumab, and ustekinumab.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
National economic burden of ulcerative colitis in the United States
National economic burden of inflammatory bowel disease in the United States
Lifetime health care costs of ulcerative colitis by age at diagnosis in 85,755 patients
“We collected data from 78,620 patients with CD, 85,755 with UC, and propensity score-matched control subjects from the Truven Health MarketScan insurance claims databases (2008‒2015).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Cost variations over a lifetime were estimated in cost-state Markov models by age at diagnosis, adjusted to 2016 U.S. dollars and discounted at 3% per annum.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“For UC, the lifetime incremental cost was $369,955 among patients who received their diagnosis at 0‒11 years, and $132,396 for individuals 70 years or older, averaging $230,102 for a diagnosis at any age. Lifetime total cost was $405,496, consisting of outpatient ($163,670), inpatient ($123,190), pharmacy ($105,142), and ER ($13,493) costs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Therefore, the prevalent populations of patients with CD or UC in the United States in 2016 are expected to incur lifetime total costs of $498 billion and $377 billion, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Annual direct costs in 52,782 commercially insured and Medicare Advantage patients with inflammatory bowel disease, 29,062 with ulcerative colitis
“There were 52,782 IBD patients (29,062 UC; 23,720 CD) included in the analysis (54.1% females). On a per-annual basis, patients with IBD incurred a greater than 3-fold higher direct cost of care compared with non-IBD controls ($22,987 vs $6956 per-member per-year paid claims)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The burden of costs was most notable in the first year after initial IBD diagnosis (mean = $26,555). The study identified several key drivers of cost for IBD patients: treatment with specific therapeutics (biologics, opioids, or steroids); ED use; and health care services associated with relapsing disease, anemia, or mental health comorbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As shown, although mean all-cause costs of IBD were stable from year to year before 2012, costs have been rising for CD and UC, particularly after 2013.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs of treatment failure with first-line advanced therapy in 5302 adults with moderate-to-severe ulcerative colitis
“Analysis of treatment failure patterns included data from 6745 patients; HCRU and cost analyses included data from 5302 patients (treatment failure cohort, n = 4295; persistent cohort, n = 1007). In the overall population, 75% experienced treatment failure within the first 12 months (median: 5.1 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment failure cohort had significantly (P < .001) higher mean costs than the persistent cohort (all-cause, $74 995 vs $56 169; UC-related, $57 096 vs $47 347) mainly attributed to inpatient admissions and outpatient visits. Dose escalation/interval shortening accounted for the highest total costs ($101 668) across treatment failure events.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization and costs in the 12 months after initiating immunosuppressant or biologic therapy in 3562 patients
“In total, 3562 patients were included in the analysis. Most patients (83.0%) used steroids in the 12 months before initiating advanced therapy. Overall, 47.8% remained steroid-free after 12 months (excluding tapering).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 12.2% of patients had a UC-related hospitalization within 12 months of initiation, with a mean (SD) total length of stay of 8.2 (8.9) days and no significant differences between biologic therapies. Mean, unadjusted, UC-related costs in the 12 months postinitiation were $42,579 and were similar between therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health care resource use and costs associated with chronic corticosteroid use
“Targeted treatment initiators included 1,886 chronic and 1,911 nonchronic corticosteroid users; conventional therapy initiators included 4,980 chronic and 5,199 nonchronic users. Chronic vs nonchronic users had 94% more inpatient days and 16% more outpatient visits among targeted treatment initiators, and 135% more inpatient days and 30% more outpatient visits among conventional therapy initiators (all P < 0.01).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean all-cause total costs per patient per year were $73,491 for chronic vs $58,884 for nonchronic users ($14,607 higher; P < 0.01) for targeted treatment initiators, and $39,335 for chronic vs $21,271 for nonchronic users ($18,065 higher; P < 0.01) for conventional therapy initiators.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization and colectomy after diagnosis in 3,893 commercially insured adults with newly diagnosed ulcerative colitis
“Among 3,893 patients with newly diagnosed UC (age at diagnosis, 41±14y; 52% male; 80% White, 7.2% Black and 8.2% Hispanic patients) followed over 4.2±3.0y, 5-year risk of IBD-related hospitalization, colectomy and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs. White patients).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Cumulative 5y risk of all-cause and IBD-related hospitalization was 17% (95% CI, 16–19) and 11% (95% CI, 10–12), respectively (Table 2). Risk of all-cause and IBD-related hospitalization remained stable over era of IBD diagnosis (Figure 2D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Indirect costs of work impairment by disease activity in 282 US patients with ulcerative colitis
“The analyses included 281 patients with CD and 282 patients with UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In UC, absenteeism (0.6%–11.9%), presenteeism (7.1%–37.1%), and overall work impairment (7.5%–41.9%) increased with increasing disease activity (all P < .0001). Annual indirect costs due to total work impairment increased with increasing disease activity (all P < .0001), from $7169/patient/year (remission) to $29 524/patient/year (moderately-to-severely active disease) in CD and $4348/patient/year (remission) to $24 283/patient/year (moderately-to-severely active disease) in UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hospitalization costs of nonelective colectomy or rectal resection in 10,280 US adults
“All adults with UC in the 2016-2020 Nationwide Readmissions Database undergoing nonelective colectomy or rectal resection were identified.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“An estimated 10,280 patients met study criteria with median index hospitalization costs of $40,300 (IQR, $26,400-$65,000). Increased time to surgery was significantly associated with a +$2500 increment in costs per day. Compared with low-volume hospitals, medium- and high-volume centers demonstrated a -$5900 and -$8200 reduction in costs, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Colectomy cost per admission used in the ICER 2020 model
Direct medical costs before and after proctocolectomy in a population-based cohort of 60 patients
“Operations included ileal-pouch anal anastomosis (n=45, mean cost of surgery/recovery period $50,530) or total proctocolectomy with Brooke ileostomy (n=15, mean cost of surgery/recovery period $39,309). In the pouch subgroup, direct medical costs on average were reduced by $9,296 (P<0.001, bootstrapped 95% CI: $324 to $15,628) in the 2-years after recovery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean costs are reported in 2007 constant dollars.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs, resource use, and quality of life with advanced therapies: systematic review of US and European observational studies
“47 publications of 40 unique cost/HCRU studies and 13 publications of nine unique HRQoL studies were included. Findings demonstrated that biologics have a positive impact on indirect costs (i.e., productivity, presenteeism, and absenteeism) and HRQoL. High costs of biologics were not always fully offset by reductions in cost and HCRU associated with disease management. For many patients, treatment switching and dose escalations were required, thus increasing drug costs, particularly when switching across treatment classes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of Ulcerative colitis on families
Caregiver burden, mental health, and work productivity: meta-analysis of 25 studies
“Out of 383 records, 25 studies met the inclusion criteria, with 12 eligible for meta-analysis. The pooled prevalence of caregiver burden was 470 per 1000 carers (95% CI: 390–560), depression at 370 per 1000, and anxiety at 400 per 1000. Loss of work productivity and activity impairment were reported in 290 and 300 per 1000 caregivers, respectively. Stress, reduced quality of life, and financial burden were also common.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only two studies assessed financial loss in caregivers for paediatric and adolescent population with IBD [32, 33]. Both studies provided absolute numbers of financial loss in caregivers as an estimate of annual productivity costs, which were calculated by the human capital approach.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Caregiver burden and lost productivity among 102 caregivers of adults with inflammatory bowel disease at a US center
“One hundred two IBD patients and their respective caregiver were included. In total, 39% of IBD caregivers experienced burden. Caregivers with burden experienced significantly more absenteeism and presenteeism (65 and 85% respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Predictors of burden included race/ethnicity, history of fistulas, diagnosis of ulcerative colitis, higher caregiver education, and hours spent caregiving.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The caregivers spent an average of 12 h (SD 25) per week on caregiving and had been caregiving for an average of 8.1 years (SD 8.5).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The employment rate in the caregiver population was 72% (n = 73), of whom 38% (n = 28) experienced absenteeism within the last week, with a mean of 9% of work hours missed (SD 17%); 57% experienced presenteeism with a mean decrease of 22% in productivity at work (SD 30%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket costs and lost wages of patients with inflammatory bowel disease
“Compared with non-IBD patients, IBD patients absorbed more than twice the out-of-pocket costs per year ($2213 vs $979), as shown in Figure 2B. Of note, this statistic does not include costs that IBD patients paid for insurance premiums (data not available) and thus likely represents an underestimate of the patient-responsible costs for health care (including IBD care). Patients with IBD also absorbed significantly higher wage-related opportunity loss based on yearly patient time costs, as shown in Figure 2C. Using the median wage, IBD patients’ lost wages were higher than the actual out-of-pocket costs on a per-year basis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Out-of-pocket and indirect costs of care reported in our analysis were likely substantial underestimates due to the data sets utilized in the analysis because the data did not include insurance premiums or other indirect costs such as actual wages lost, time for caregivers, or transportation required for health care services.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work impairment and estimated lost wages in employed US patients with moderate-to-severe ulcerative colitis
“Patients with active disease in the US and EU5 reported the highest levels of presenteeism (adjusted means = 31.0 and 49.1%, respectively), overall work impairment (adjusted means = 34.5 and 54.4%), and activity impairment (adjusted means = 34.7 and 47.6%) (Figs. 4 and 5). Patients with active disease in the US had significantly higher levels of absenteeism than patients in remission (adjusted means = 9.2% vs. 2.0%, P < 0.05)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although a formal evaluation of indirect cost estimates is beyond the scope of this study, using a human capital approach, the levels of overall work impairment we observed would equate to $15,400 in lost wages per employed patient with UC per year in the US (based on annualized 2017 median weekly earnings from the US Bureau of Labor Statistics [19])” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Work absence and family decisions in the UC Narrative global survey
“Overall, the majority (83%) of patients agreed that having UC impacted their work, with 74% of employed patients reporting work absence because of their UC and missing a mean of 8.1 working days (SD, 16.7) in the past 12 months because of their UC symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“However, 39% of patients had not told their employer about their UC diagnosis because of a fear of repercussions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“More than one-third of patients (37%) reported that UC had influenced their decisions regarding family (including deciding not to have children, to have any more children, postponing having children, deciding to adopt, stopping treatment to start a family, or postponing/ending/avoiding romantic relationships).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Effect of bowel urgency on work or school among US patients with moderate-to-severe ulcerative colitis
Economic impact of diagnostic testing
Cost-effectiveness of fecal calprotectin screening before endoscopy for suspected inflammatory bowel disease in the United States
“We constructed a decision analytic tree to compare the cost-effectiveness of measuring FC before endoscopy examination with that of direct endoscopic evaluation alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adults, FC screening saved $417/patient but delayed diagnosis for 2.2/32 patients with IBD, among 100 screened patients. In children, FC screening saved $300/patient but delayed diagnosis for 4.8/61 patients with IBD, among 100 screened patients. If endoscopic biopsy analysis remained the standard for diagnosis, direct endoscopic evaluation would cost an additional $18,955 in adults and $6250 in children to avoid 1 false negative result from FC screening.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pre-test probabilities for IBD of ≤75% in adults and ≤65% in children made FC screening cost-effective, but cost ineffective if the probabilities were ≥85% and ≥78% in adults and children, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adopting a third-party payer perspective, only direct costs were considered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fecal calprotectin for ongoing disease monitoring
Approaches to treatment
Current treatment options and standard of care
Aminosalicylates
Recommendations against 5-ASA added to advanced therapy: ACG 2025 guideline
Recommendations for 5-ASA in mildly to moderately active disease: ACG 2025 guideline
Recommendation to stop 5-ASA after escalation: AGA 2024 living guideline
“13. In adult outpatients with moderate-to-severe UC, who have failed 5-ASAs, and have escalated to therapy with immunomodulators or advanced therapies, the AGA suggests stopping 5-ASAs. [Conditional recommendation, low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Large observational studies have suggested no difference in the risk of adverse clinical outcomes between patients who continue vs. stop 5-ASA after starting advanced therapies or immunomodulators99–101.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The guideline panel also acknowledged that one proposed benefit of long-term 5-ASA use is potential chemoprevention effect against colorectal cancer, but this remains unproven.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendations for 5-ASA induction, maintenance, and discontinuation: ECCO 2026 guideline
Efficacy of oral 5-ASA versus placebo: ECCO 2026 meta-analysis
Indication of delayed-release mesalamine tablets
Remission at Week 8 in two placebo-controlled induction trials of delayed-release mesalamine tablets
| Dose | Study 1 (n=262) n/N (%) | Study 2 (n=255) n/N (%) |
|---|---|---|
| Mesalamine 2.4 g/day | “30/88 (34)” | “34/84 (41)” |
| Mesalamine 4.8 g/day | “26/89 (29)” | “35/85 (41)” |
| Placebo | “11/85 (13)” | “19/86 (22)” |
Warnings and precautions for mesalamine
Corticosteroids
Recommendations for corticosteroid induction and against corticosteroid maintenance: ACG 2025 guideline
Efficacy of systemic corticosteroids and budesonide MMX: ACG 2025 guideline
Recommendations for oral prednisolone and colonic-release corticosteroids: ECCO 2026 guideline
Indication and induction efficacy of budesonide extended-release tablets
Induction of remission in Studies 1 and 2 of budesonide extended-release tablets
| Treatment group | Study 1 n/N (%) | Study 2 n/N (%) |
|---|---|---|
| Budesonide 9 mg | “22/123 (17.9)” | “19/109 (17.4)” |
| Budesonide 6 mg | “16/121 (13.2)” | “9/109 (8.3)” |
| Placebo | “9/121 (7.4)” | “4/89 (4.5)” |
Warnings and precautions for budesonide extended-release tablets
Complications of chronic corticosteroid use in US adults with ulcerative colitis
“Patients with long-term or chronic use of CS may present with both short- and long-term complications including infection, hypertension, new-onset diabetes mellitus, osteoporosis, cataracts, and glaucoma.5,6” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although CS therapy is efficacious in inducing remission among most patients with UC, more than 90% of patients will experience an adverse event, and CS dependence is common.4,8,9” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The prevalence of several CS-related complications among targeted treatment initiators was significantly higher in chronic CS users compared with nonchronic CS users, with proportions of 55.5% vs 52.4% for patients with infection, leading to an odds ratio (OR) of 1.14 (95% CI = 1.00-1.29; P = 0.0500); 14.5% vs 7.4% for bone loss, leading to an OR of 2.13 (95% CI = 1.72-2.64; P < 0.001); 5.6% vs 3.0% for venous thromboembolism, leading to an OR of 1.93 (95% CI = 1.39-2.68; P < 0.001); and 2.5% vs 0.3% for adrenocortical insufficiency, leading to an OR of 8.24 (95% CI = 3.50-19.37; P < 0.001; Figure 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Thiopurines and methotrexate
Recommendations for thiopurines and methotrexate: ACG 2025 guideline
Efficacy of thiopurines and methotrexate: ACG 2025 guideline
Recommendations for immunomodulator monotherapy and combination therapy: AGA 2024 living guideline
“5. In adult outpatients with moderate-to-severe UC, the AGA suggests AGAINST using thiopurine monotherapy for induction of remission. [Conditional recommendation, very low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“6. In adult outpatients with moderate-to-severe UC in remission, the AGA suggests using thiopurine monotherapy, rather than no treatment, for maintenance of remission, typically induced by corticosteroids. [Conditional recommendation, low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“7. In adult outpatients with moderate-to-severe UC, the AGA suggests AGAINST using methotrexate monotherapy, for induction or maintenance of remission. [Conditional recommendation, low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“8. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of infliximab in combination with an immunomodulator over infliximab or an immunomodulator alone. [Conditional recommendation, moderate certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“9. In adult outpatients with moderate-to-severe UC, the AGA suggests the use of adalimumab or golimumab in combination with an immunomodulator over adalimumab, golimumab or immunomodulator monotherapy. [Conditional recommendation, low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy and harms of thiopurines and combination therapy: AGA 2024 living guideline
“On meta-analysis, thiopurines were more effective than placebo or 5-ASA for decreasing risk of disease relapse (RR, 0.61; 95% CI, 0.49–0.77) among patients with inactive UC (in remission) (eFigure 14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At week 16, the primary endpoint of corticosteroid-free clinical remission was achieved by 39.7% of patients receiving combination therapy compared to 22.1% of infliximab treated patients and 23.7% of azathioprine treated patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Short- and long-term side effects of thiopurines and methotrexate are well-recognized including risk of bone marrow suppression, hepatotoxicity (including liver fibrosis with long-term use of methotrexate), non-melanoma skin cancer and lymphoma, especially with thiopurines78.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendations for thiopurines: ECCO 2026 guideline
Tumor necrosis factor inhibitors
Recommendations for anti-TNF therapy: ACG 2025 guideline
Pivotal trial efficacy of infliximab, adalimumab, and golimumab: ACG 2025 guideline
Efficacy tiers by prior advanced-therapy exposure: AGA 2024 living guideline
“In patients who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib, risankizumab, guselkumab) or an intermediate efficacy medication (golimumab, ustekinumab, tofacitinib, filgotinib, mirikizumab), rather than a lower efficacy medication (adalimumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients who have previously been exposed to one or more advanced therapies, particularly tumor necrosis factor-α (TNF) antagonists, the AGA suggests using a higher efficacy medication (tofacitinib, upadacitinib, ustekinumab) or an intermediate efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a lower efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Infliximab has a possibly important benefit in achieving remission compared with adalimumab, mirikizumab, tofacitinib, and filgotinib with a low certainty of evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Notably, there was no RCT for infliximab or golimumab in patients with prior exposure to biologics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lymphoma risk with TNF antagonists: AGA 2024 living guideline
“In a French population-based study, Lemaitre and colleagues estimated the annual incidence of lymphoma in patients treated with TNF antagonist monotherapy vs. unexposed patients to be 0.41 per 1000 person-years vs. 0.26 per 1000 person-years; after adjusting for potential confounders, the risk of lymphoma was 2.4-times higher in patients treated with TNF antagonist monotherapy25.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients exposed to combination therapy had six-fold increased risk of lymphoma, as compared to unexposed patients, and 2.3–2.5 times higher risk as compared to patients exposed to monotherapy with either agent.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendations and meta-analysis for anti-TNF agents: ECCO 2026 guideline
Boxed warning for TNF blockers: infliximab label
Adalimumab limitation of use after TNF blocker failure
Anti-integrin antibodies
Recommendations for vedolizumab: ACG 2025 guideline
Pivotal trial efficacy of vedolizumab: ACG 2025 guideline
VARSITY head-to-head trial and comparative safety: AGA 2024 living guideline
“The only head-to-head trial was the VARSITY trial where 769 patients with moderate-to-severe UC were randomized to receive either vedolizumab (n=383) or adalimumab (n=386)38. At week 52, a higher rate of clinical remission was observed in the vedolizumab treated patients (31.3%) compared to adalimumab (22.5%). Corticosteroid-free remission rates, however, were higher with adalimumab (21.8%) compared to vedolizumab (12.6%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This trial noted no difference between the two agents in maintaining clinical remission (20.3% vs 16.0%) in this subpopulation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In observational studies, vedolizumab was associated with a lower risk of serious infections compared with TNF antagonists in patients with UC69, 70; there was paucity of evidence for comparative safety of other agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy of vedolizumab by prior biologic exposure: AGA 2024 network meta-analysis
“Intriguingly, the difference in relative efficacy of a drug in biologic-exposed vs. biologic-naïve patients was significantly greater for some drugs, most notably for vedolizumab and ozanimod in our analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendations and meta-analysis for vedolizumab: ECCO 2026 guideline
Comparative clinical effectiveness of vedolizumab: ICER 2026 special assessment
Indication and warnings for vedolizumab
Interleukin-12/23 inhibitors
Recommendations for ustekinumab: ACG 2025 guideline
UNIFI pivotal trial efficacy of ustekinumab: ACG 2025 guideline
Comparative efficacy of ustekinumab after prior advanced therapy: AGA 2024 living guideline
“Ustekinumab demonstrated a likely important benefit over adalimumab, vedolizumab, ozanimod, etrasimod, and mirikizumab with a moderate certainty of evidence.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Biosimilars of infliximab, adalimumab, and ustekinumab can be considered equivalent to their originator drug in their efficacy in terms of therapy selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendations and trial results for ustekinumab: ECCO 2026 guideline
Indication and warnings for ustekinumab
Interleukin-23 p19 inhibitors
ACG 2025 guideline: recommendations for induction and maintenance
Pivotal trial results for guselkumab and mirikizumab: ACG 2025 evidence summary
Comparison with ustekinumab and switching within the class: ACG 2025
ECCO 2026 guideline: recommendations and risankizumab trial results
Network meta-analyses: rankings of interleukin-23 p19 inhibitors
“Ater excluding JAK inhibitors, amongst biologic-naïve patients with moderately to severely active UC, risankizumab (P-score 0.86) and ozanimod (P-score 0.83) were ranked highest for induction of clinical remission (Figure 1b).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Risankizumab ranked first in the induction of histological remission (89.4%), followed by guselkumab (88.3%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Anti-p19 inhibitors, including risankizumab, subcutaneous guselkumab, and mirikizumab, were associated with the most favorable safety profiles for serious adverse events and adverse events leading to discontinuation, although confidence in safety estimates was lower.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mirikizumab: mechanism and dosing in ulcerative colitis
Risankizumab: mechanism and dosing in ulcerative colitis
Guselkumab: mechanism and dosing in ulcerative colitis
Janus kinase inhibitors
ACG 2025 guideline: recommendations for induction and maintenance
Pivotal trial results for tofacitinib and upadacitinib: ACG 2025 evidence summary
U.S. positioning after TNF antagonist failure: ACG 2025
Restricted first-line use: AGA 2024 guideline
ECCO 2026 guideline: recommendations, safety, and European risk minimization
Tofacitinib: U.S. indication in ulcerative colitis
Upadacitinib: U.S. indication and dosing in ulcerative colitis
Network meta-analyses: rankings of Janus kinase inhibitors
“With the inclusion of JAK inhibitors as first-line therapy, upadacitinib was more efficacious compared with all other medications except ozanimod and risankizumab with low to moderate certainty evidence. In patients with prior biologic exposure, upadacitinib, tofacitinib and ustekinumab were ranked highest for achieving remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upadacitinib ranked highest in inducing clinical remission (99.6%), and endoscopic improvement (99.2%), followed by risankizumab (91.4%) and (82.3%), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Upadacitinib demonstrated the highest relative efficacy for clinical remission (risk ratio, 6.90; 95% confidence interval, 3.54-12.45; P score, 0.95; high confidence) and endoscopic improvement (risk ratio, 5.29; 95% confidence interval, 3.38-8.28; P score, 0.97; moderate confidence).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In re‐randomised studies, upadacitinib 30 mg o.d. ranked first for clinical remission (RR of failure to achieve clinical remission = 0.52; 95% CI 0.44–0.61, p‐score 0.99) and endoscopic improvement (RR = 0.43; 95% CI 0.35–0.52, p‐score 0.99).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The guideline does not provide a hierarchy of treatments, due predominantly to the lack of head-to-head data, but network meta-analysis (NMA) of trials for induction and maintenance of moderate to severe UC demonstrate a large magnitude of effect for upadacitinib and tofacitinib, with moderate magnitude of effect for risankizumab, filgotinib and ozanimod, and a small magnitude of effect for infliximab, etrasimod, golimumab, mirikizumab, ustekinumab and vedolizumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Medicare drug price negotiation: tofacitinib selected for the third cycle
Sphingosine-1-phosphate receptor modulators
ACG 2025 guideline: recommendations for induction and maintenance
Mechanism and pivotal trial results: ACG 2025 evidence summary
ECCO 2026 guideline: recommendations and etrasimod safety
Ozanimod: indication, mechanism, dosing, and monitoring
Etrasimod: indication, mechanism, and dosing
Network meta-analyses: rankings of sphingosine-1-phosphate receptor modulators
“After excluding JAK inhibitors as potential first-line treatment (in accordance with FDA), low-certainty evidence supports clinically important benefit with infliximab, ozanimod, risankizumab and guselkumab over adalimumab and mirikizumab for achieving remission with induction therapy in biologic-naïve patients with moderate-severe UC, with risankizumab and ozanimod being ranked the highest for induction of clinical remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Calcineurin inhibitors
Rescue therapy in acute severe ulcerative colitis: ACG 2025
Tacrolimus in steroid-refractory disease: ACG 2025
Cyclosporine compared with infliximab: ECCO 2026
Third-line sequential rescue therapy: ECCO 2026
Calcineurin inhibitors prohibited during obefazimod open-label maintenance
Colectomy
Indications for surgical consultation and colectomy: ACG 2025
ECCO 2026 surgical guideline: timing, reconstruction, and center volume
Cumulative risk of colectomy: meta-analysis of population-based cohorts
“On meta-analysis, the cumulative risk of colectomy 1-, 5-, and 10-years after diagnosis was 4.0% (95% CI, 3.3–5.0), 8.8% (95% CI, 7.7–10.0) and 13.3% (95% CI, 11.3–15.5), respectively, with considerable heterogeneity (I2=95–98%) (Figures 1A–C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cumulative risk of colectomy in newly diagnosed U.S. adults, 2007 to 2023
Hospitalization cost of nonelective colectomy in the United States
“An estimated 10,280 patients met study criteria with median index hospitalization costs of $40,300 (IQR, $26,400-$65,000). Increased time to surgery was significantly associated with a +$2500 increment in costs per day.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Colectomy cost input in the ICER 2020 model
Limitations of current therapies
Summary: limitations of current therapies
A review states that the highest response to medical therapies “ranges from 30% to 60% in clinical trials”, and another review states that “10-20% of patients still require proctocolectomy for medically refractory disease.” The ACG 2025 guideline states that up to one-fifth of patients receiving anti-TNF agents may not respond initially and that “an additional 10%–15% may lose response every year”; the ECCO 2026 guideline reports that 40% of patients on vedolizumab maintenance lose response. Among 3,562 patients initiating advanced therapy, 47.8% remained steroid-free after 12 months, and mean UC-related costs in the 12 months after initiation were $42,579. The two oral classes carry restrictions: the tofacitinib label carries a boxed warning for serious infections, mortality, malignancy, major adverse cardiovascular events, and thrombosis, and both U.S. JAK inhibitor labels indicate them in ulcerative colitis after an inadequate response or intolerance to one or more TNF blockers (for upadacitinib, after at least one approved systemic therapy when TNF blockers are clinically inadvisable); the S1P receptor modulators require pre-treatment assessments, and the ACG 2025 guideline states that significant cardiovascular disease and cardiac conduction defects, among other conditions, contraindicate ozanimod. Biologics require injections or intravenous infusions, which Abivax describes as resulting in “patient inconvenience and burden”.
Primary nonresponse and loss of response
Continued corticosteroid use after starting advanced therapy
“In total, 3562 patients were included in the analysis. Most patients (83.0%) used steroids in the 12 months before initiating advanced therapy. Overall, 47.8% remained steroid-free after 12 months (excluding tapering).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean, unadjusted, UC-related costs in the 12 months postinitiation were $42,579 and were similar between therapies.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Boxed warning on Janus kinase inhibitors
Cardiac contraindications to sphingosine-1-phosphate receptor modulators
Administration burden and waning efficacy: manufacturer statement
Place in treatment, anticipated use, and care setting
Summary: anticipated place in therapy
Obefazimod is investigational, and no labeled indication exists. Abivax describes its pre-NDA interaction with the FDA as concerning obefazimod “for the treatment of adults with moderately to severely active ulcerative colitis”. ABTECT-1 and ABTECT-2 enrolled participants with a modified Mayo score of 5 or more who had an inadequate response, loss of response, or intolerance to at least one prior therapy, including corticosteroids, immunosuppressants, biologics, S1P receptor modulators, or JAK inhibitors, with no upper limit; 602 of 1,272 participants (47.3%) had a prior inadequate response to an advanced therapy. Obefazimod is taken orally once daily, whereas the IL-23 p19 inhibitors require intravenous induction (or subcutaneous induction for guselkumab) and subcutaneous maintenance.
Abivax states that it hopes “to position obefazimod as a potential first-line advanced therapy” and that there is no guarantee it would be approved for that use. Abivax estimates that approximately 300,000 moderate-to-severe U.S. patients, out of an estimated 500,000, are on conventional therapy or steroids only, and its research reported that physicians would likely initiate obefazimod in this population “where reluctance to advanced therapies hinder their use.” A Wedbush analyst noted that a boxed warning would limit commercial differentiation against JAK inhibitors.
The AGA 2024 guideline suggests early use of advanced therapies rather than gradual step-up after 5-aminosalicylate failure, and ranks therapies by efficacy separately for advanced therapy-naive and -exposed patients. The ECCO 2026 guideline recommends no treatment or class over another as first-line or subsequent therapy, apart from vedolizumab over adalimumab. The ACG 2025 guideline did not use indirect or post hoc data for its positioning recommendations and states that third-party payers and step therapy requirements “should not come between the patient and their healthcare team”. The BSG 2025 guideline provides no hierarchy. In a cohort of patients newly diagnosed with ulcerative colitis in 2019 to 2023, cumulative 1-year and 5-year use of advanced therapy was 27% and 38%.
Proposed indication named in the pre-NDA announcement
Population studied in the phase 3 induction trials
“The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Obefazimod (Obe), an oral, once‐daily (QD), small molecule which enhances expression of microRNA‐124 was studied in patients (pts) with moderately to severely active ulcerative colitis (UC) in Phase 2 studies [1–3].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Manufacturer positioning as an oral advanced therapy
Manufacturer estimate of patients on conventional therapy
Analyst view on positioning against Janus kinase inhibitors
Guideline sequencing: early advanced therapy and absence of a hierarchy
“In adult outpatients with moderate-severe UC, the AGA suggests early use of advanced therapies with or without immunomodulator therapy, rather than gradual step up after failure of 5-aminosalicylates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A summary of recommendations from the 2025 BSG IBD guidelines regarding the use of advanced therapies for induction and maintenance of remission in patients with moderate to severe IBD. Medications are not listed hierarchically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Current use of advanced therapy in newly diagnosed U.S. adults
Analyst commentary on cancer risk and a possible boxed warning, June 2026
Heterogeneity of treatment effect
Summary: response by prior advanced therapy exposure
In the pooled ABTECT induction trials, 47.3% of participants had a prior inadequate response to an advanced therapy (AT-IR). The placebo-adjusted difference in clinical remission at week 8 with obefazimod 50 mg was 10.1% in participants with AT-IR and 22.4% in those without; with 25 mg, the difference was lower than with 50 mg in participants with AT-IR, and the two doses performed similarly in participants without AT-IR. In participants with prior JAK inhibitor failure, the pooled placebo-adjusted difference in clinical response with 50 mg was 34%. In the maintenance trial, clinical remission at Week 52 occurred in 72 of 117 (25 mg) and 62 of 105 (50 mg) participants against 15 of 120 with placebo among AT-IR-naive participants, and in 26 of 76 and 38 of 90 against 5 of 72 among participants with prior AT-IR. In the phase 2b open-label maintenance study, clinical remission at week 96 was 63.8% in participants naive to biologics or JAK inhibitors, and 38.8% of those with prior inadequate response were in clinical remission at both weeks 48 and 96. The same direction of effect is reported for comparators: the ACG 2025 guideline states that patients have higher response and remission rates with their first therapies than after failure of other advanced therapies, and the AGA 2024 guideline places different agents in its higher-efficacy tier for advanced therapy-naive and -exposed patients. In a 2026 network meta-analysis of induction trials, obefazimod and upadacitinib showed the highest efficacy in AT-naive patients, and upadacitinib, ustekinumab, and tofacitinib ranked highest in AT-experienced patients. All obefazimod subgroup p-values are nominal.
Obefazimod induction: efficacy with and without prior inadequate response to advanced therapy
“Among pts who participated in ABTECT‐1, ABTECT‐2, and the pooled analysis, 45.3% (288/636), 49.4% (314/636), and 47.3% (602/1272) were AT‐IR‐Yes, respectively; 54.7% (348/636), 50.6% (322/636), 52.7% (670/1272) were AT‐IR‐No.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In ABTECT‐1, ABTECT‐2, and pooled, a higher proportion of the AT‐IR‐Yes subgroup receiving Obe‐50 achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 12.7%, p = 0.0039; ABTECT‐2 7.6%, p = 0.0652, pooled 10.1%, p = 0.0009).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AT‐IR‐Yes subgroup, the difference from PBO across all efficacy measures was lower for pts receiving Obe‐25 relative to Obe‐50 (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the AT‐IR‐No subgroup, larger proportions achieved all efficacy measures relative to PBO including clinical remission (Obe‐50‐PBO difference: ABTECT‐1 25.0%, p < 0.0001; ABTECT‐2 19.4%, p = 0.0004; pooled 22.4%, p < 0.0001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the subset of pts who failed JAKi, higher proportion of pts receiving Obe‐50 or Obe‐25 achieved clinical response versus PBO. The difference from PBO in clinical response for Obe‐25 and Obe‐50 was similar across lines of treatment, from AT‐IR‐No through 4+ AT‐IRs (Table).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obefazimod induction: prior Janus kinase inhibitor failure and number of prior advanced therapies
Obefazimod maintenance: efficacy with and without prior inadequate response to advanced therapy
Obefazimod phase 2b open-label maintenance: participants naive to or refractory to biologics or JAK inhibitors
“Among the 98 patients with inadequate response to biologics (anti-TNFα, vedolizumab, ustekinumab) or JAK inhibitors, 74/98 (75.5%) achieved clinical response at week 48 and 66/98 (67.3%) at week 96; 38/98 patients (38.8%) were in clinical remission at both weeks 48 and 96 (Figure 4).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In this subset, clinical remission was achieved by 81/119 patients (68.1%) at week 48 and by 76/119 patients (63.8%) at week 96; 89/119 (74.8%) and 82/119 patients (68.9%) had endoscopic improvement, and 54/119 (45.4%) and 58/119 patients (48.7%) achieved endoscopic remission at weeks 48 and 96, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rates of clinical remission, endoscopic improvement, and endoscopic remission at weeks 48 and 96 were numerically higher, from 25% to 33%, in the subgroup of naïve relative to refractory patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Obefazimod long-term extension after dose reduction to 25 mg, by prior advanced therapy
Network meta-analysis including obefazimod, stratified by prior advanced therapy
“Analyses were stratified by prior exposure to ATs.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In AT-naïve patients, obefazimod and upadacitinib showed the highest efficacy, whereas in AT-experienced patients, upadacitinib, ustekinumab, and tofacitinib ranked highest.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Comparator rankings in biologic-exposed patients: network meta-analyses
“Overall, upadacitinib (P-score 0.93), tofacitinib (P-score 0.88), and ustekinumab (P-score 0.87) ranked highest in inducing remission in biologic-exposed patients with moderate-to-severely active UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the biologic/Janus kinase inhibitor (JAKi)-naïve population, induction studies showed similar clinical response and remission rates across most interventions, with upadacitinib demonstrating significant improvements versus most other interventions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline efficacy tiers by prior advanced therapy exposure: AGA 2024
“In adult outpatients with moderate-to-severe UC who are naïve to advanced therapies, the AGA suggests using a HIGHER efficacy medication (infliximab, vedolizumab, ozanimod, etrasimod, upadacitinib*, risankizumab, guselkumab) OR an INTERMEDIATE efficacy medication (golimumab, ustekinumab, tofacitinib*, filgotinib*, mirikizumab), rather than a LOWER efficacy medication (adalimumab).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In adult outpatients with moderate-to-severe UC who have previously been exposed to one or more advanced therapies, particularly TNF antagonists, the AGA suggests using a HIGHER efficacy medication (tofacitinib, upadacitinib, ustekinumab) OR an INTERMEDIATE efficacy medication (filgotinib, mirikizumab, risankizumab, guselkumab), rather than a LOWER efficacy medication (adalimumab, vedolizumab, ozanimod, etrasimod).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Phase 3 randomized trial of ozanimod against placebo, ozanimod was significantly more effective than placebo in achieving clinical remission with rates of 23% (vs 7%) and 17% (vs. 8%) in biologic-naïve and single biologic-exposed patients. In contrast, in patients who had been on ≥2 biologics previously, ozanimod was no more effective than placebo (4% vs. 3%) in inducing clinical remission.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Lower response after prior advanced therapy: ACG 2025
Comparator subgroups by prior exposure: ECCO 2026
Care management intervention strategies
Treat-to-target with endoscopic improvement and fecal calprotectin: ACG 2025
Monitoring schedule after starting advanced therapy: AGA 2024
“Initiation of advanced therapy should be followed by monitoring for symptomatic response within 3 months of initiation, symptomatic and biochemical remission within 3–6 months, and endoscopic improvement/ remission within 6–12 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“On-treatment monitoring for potential toxicity from immunosuppressive therapies, such as periodic monitoring of hemogram, chemistries and transaminases, should be performed, according to drug label.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treat-to-target, escalation, and multidisciplinary care: ECCO 2026
Therapeutic drug monitoring
Payer utilization management: ACG 2025 position
Pre-treatment screening required by labels of oral advanced therapies
Obefazimod-specific care management program
No evidence found.
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.
Expected outcomes of therapy
Summary: expected outcomes
STRIDE-II sets clinical remission and endoscopic healing as long-term treatment targets, adds absence of disability and restoration of quality of life, and sets symptomatic relief and normalization of serum and fecal markers as short-term targets; histological healing in ulcerative colitis is not a formal target. The ACG 2025 guideline recommends treating to endoscopic improvement (Mayo endoscopic subscore 0 or 1) to increase the likelihood of sustained steroid-free remission and to prevent hospitalization and surgery, and the ECCO 2026 guideline describes treat-to-target beyond steroid-free clinical remission as not yet conclusively validated. In the pooled ABTECT induction trials, the placebo-adjusted clinical remission rate at Week 8 with obefazimod 50 mg was 16.4%. In the ABTECT maintenance trial, clinical remission at Week 44 was 50.8% with 25 mg and 51.3% with 50 mg against 10.4% with placebo among 580 induction responders. At week 8 of induction, 37% of participants on 50 mg reported no bowel urgency against 18.1% on placebo. In Study 108, 68% (88/130) of participants were in clinical remission at week 144 after dose reduction to 25 mg. These obefazimod results come from press releases and congress presentations; no peer-reviewed full report of ABTECT has been published.
Treatment targets: STRIDE-II
“STRIDE-II confirmed STRIDE-I long-term targets of clinical remission and endoscopic healing and added absence of disability, restoration of quality of life, and normal growth in children. Symptomatic relief and normalization of serum and fecal markers have been determined as short-term targets. Transmural healing in Crohn's disease and histological healing in ulcerative colitis are not formal targets but should be assessed as measures of the remission depth.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Goals of management: ACG 2025
Mucosal and histologic healing and long-term outcomes: ECCO 2026
Obefazimod: clinical remission and secondary endpoints after 44 weeks of maintenance
Obefazimod: patient-reported outcomes after 8 weeks of induction
Obefazimod: durability of clinical remission over three years
Health-related quality of life expected with comparator advanced therapies
“During induction, clinically meaningful improvements in IBDQ were observed with upadacitinib, filgotinib, and guselkumab. During maintenance, upadacitinib 30 mg and vedolizumab showed HRQoL benefits, although clinical meaningfulness was not consistently demonstrated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote